Document Type
Response or Comment
Publication Date
8-17-2026
Abstract
Thank you for the opportunity to provide written comments in response to the Medicare Drug Price Negotiation Program proposed rule published on June 16, 2026 in the Federal Register. [1] We are answering as academic researchers with experience in medicine, pharmacy, biomedical research, and the biopharmaceutical industry. Our perspective is informed by extensive, published research on the economics and finance of pharmaceutical innovation, the value created by new medicines, and the impacts of the Inflation Reduction Act (IRA).
We applaud the accomplishment of the IRA in establishing the precedent for the government to negotiate “fair market prices” for drugs on terms that address both the affordability of healthcare and the need for industry to receive a reasonable return on investment. We are pleased to see the normative business practice of price negotiation codified in these “final guidelines.”
Recommended Citation
Ledley, Fred D. M.D. and Zhou, Edward Pharm. D., 2026. Comments Re: Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program, CISI Publication.
Included in
Pharmaceutics and Drug Design Commons, Pharmacoeconomics and Pharmaceutical Economics Commons, Pharmacy Administration, Policy and Regulation Commons
